Tag: BAQSIMI

Eli Lilly Q2 2023 financial results highlight robust 28% revenue growth

businessnewstoday- August 9, 2023

Eli Lilly and Company (NYSE: LLY) unveiled their Q2 2023 financials, showcasing a 28% revenue enhancement, predominantly driven by volume growth from Mounjaro, Verzenio, Jardiance, ... Read More

Lilly to sell hypoglycemia drug BAQSIMI to Amphastar Pharmaceuticals

businessnewstoday- April 24, 2023

Eli Lilly and Company (Lilly) has agreed to sell its severe hypoglycemia drug BAQSIMI to Amphastar Pharmaceuticals in a deal potentially worth up to $1.07 ... Read More